questionsmedicales.fr
Composés chimiques organiques
Hydrocarbures
Hydrocarbures cycliques
Hydrocarbures aromatiques
Dérivés du benzène
Phénols
Catéchols
Masoprocol
Masoprocol : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Masoprocol
Diagnostic médical
Essais cliniques
Évaluation des symptômes
Symptômes
2
Inflammation
Cancer de la peau
Effets secondaires
Irritation cutanée
Prévention
2
Prévention des maladies
Traitement
Prévention
Exposition au soleil
Traitements
2
Traitement topique
Lésions cutanées
Administration locale
Crème
Complications
2
Complications
Infections cutanées
Interactions médicamenteuses
Consultation médicale
Facteurs de risque
2
Facteurs de risque
Allergies cutanées
Immunodépression
Surveillance médicale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Masoprocol : Questions médicales les plus fréquentes",
"headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-01",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Masoprocol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Catéchols",
"url": "https://questionsmedicales.fr/mesh/D002396",
"about": {
"@type": "MedicalCondition",
"name": "Catéchols",
"code": {
"@type": "MedicalCode",
"code": "D002396",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.455.426.559.389.657.166"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Masoprocol",
"alternateName": "Masoprocol",
"code": {
"@type": "MedicalCode",
"code": "D009637",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammed Baqur S Al-Shuhaib",
"url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib",
"affiliation": {
"@type": "Organization",
"name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Sarfaraz Alam",
"url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam",
"affiliation": {
"@type": "Organization",
"name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland."
}
},
{
"@type": "Person",
"name": "Salman Ali Khan",
"url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan",
"affiliation": {
"@type": "Organization",
"name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."
}
},
{
"@type": "Person",
"name": "Hayder O Hashim",
"url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Daniel H Obayes",
"url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes",
"affiliation": {
"@type": "Organization",
"name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The pathophysiology of the cell cycle in cancer and treatment strategies using various cell cycle checkpoint inhibitors.",
"datePublished": "2023-10-04",
"url": "https://questionsmedicales.fr/article/37864989",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prp.2023.154854"
}
},
{
"@type": "ScholarlyArticle",
"name": "The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36253861",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13045-022-01360-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prevalent and dynamic binding of the cell cycle checkpoint kinase Rad53 to gene promoters.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36520028",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7554/eLife.84320"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022).",
"datePublished": "2023-01-19",
"url": "https://questionsmedicales.fr/article/36620912",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13543776.2022.2166827"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cucurbitacin IIb Extracted from Hemsleya penxianensis Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells by Regulating Cell Cycle Checkpoints and Mitochondrial Apoptotic Pathway.",
"datePublished": "2023-04-22",
"url": "https://questionsmedicales.fr/article/37086373",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11130-023-01058-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures",
"item": "https://questionsmedicales.fr/mesh/D006838"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrocarbures cycliques",
"item": "https://questionsmedicales.fr/mesh/D006844"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hydrocarbures aromatiques",
"item": "https://questionsmedicales.fr/mesh/D006841"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dérivés du benzène",
"item": "https://questionsmedicales.fr/mesh/D001555"
},
{
"@type": "ListItem",
"position": 7,
"name": "Phénols",
"item": "https://questionsmedicales.fr/mesh/D010636"
},
{
"@type": "ListItem",
"position": 8,
"name": "Catéchols",
"item": "https://questionsmedicales.fr/mesh/D002396"
},
{
"@type": "ListItem",
"position": 9,
"name": "Masoprocol",
"item": "https://questionsmedicales.fr/mesh/D009637"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Masoprocol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Masoprocol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Masoprocol",
"description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cell+Cycle+Checkpoints#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Masoprocol",
"description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cell+Cycle+Checkpoints#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Masoprocol",
"description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cell+Cycle+Checkpoints#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Masoprocol",
"description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cell+Cycle+Checkpoints#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Masoprocol",
"description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cell+Cycle+Checkpoints#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Masoprocol",
"description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cell+Cycle+Checkpoints#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le masoprocol est-il diagnostiqué ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes le masoprocol peut-il traiter ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés."
}
},
{
"@type": "Question",
"name": "Le masoprocol provoque-t-il des effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées avec le masoprocol ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux."
}
},
{
"@type": "Question",
"name": "Dans quel type de traitement le masoprocol est-il utilisé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés."
}
},
{
"@type": "Question",
"name": "Comment le masoprocol est-il administré ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement appliqué localement sous forme de crème ou de gel."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le masoprocol ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il interagir avec d'autres médicaments ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires du masoprocol ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
The cell cycle is the series of events that occur in a cell leading to its division and duplication. It can be divided into two main stages: interphase and mitosis. Interphase is the longest stage of ...
Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and maintaining gen...
Replication of the genome must be coordinated with gene transcription and cellular metabolism, especially following replication stress in the presence of limiting deoxyribonucleotides. The...
DNA damage repair in most malignancies with mutation of p53 is more dependent on the G2/M checkpoint. Wee1 kinase is a key regulator of the G2/M checkpoint. If Wee1 is inhibited, it results in cells w...
This review summarizes for the first time the structures of small-molecule inhibitors of Wee1 reported in patents published from 2003 to 2022 and the recent clinical developments. It also provides per...
Although the small-molecule inhibitors of Wee1, Adavosertib, and ZN-C3 have entered the clinical phase II, the clinical toxicity exhibited by Adavosertib remains the subject of greater concern. The us...
Cucurbitacin IIb (CuIIb) extracted from Hemsleya penxianensis has been demonstrated anticancer activity in many malignancies, however, its effect against bladder cancer cells and the molecular mechani...
Citrinin (CIT), a polyketide mycotoxin produced by...
Although clinical antitumor activity of Tumor Treating Fields (TTFields) has been reported in malignant pleural mesothelioma (MPM) patients, the mechanisms behind the different selectivity displayed b...
The Ser/Thr protein phosphatase 2 A (PP2A) regulates the dephosphorylation of many phosphoproteins. Substrate recognition are mediated by B regulatory subunits. Here, we report the identification of a...
Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype and accounts for approximately 15-20% of breast cancer cases. In this study, we identified KLHL29, which is an understudie...
As a DNA surveillance mechanism, cell cycle checkpoint has recently been discovered to be closely associated with lung adenocarcinoma (LUAD) prognosis. It is also an essential link in the process of D...
In this study, DDR-related genes with cell cycle checkpoint function (DCGs) were selected to investigate their effects on the prognosis of LUAD. The TCGA-LUAD cohort and two GEO external validation co...
4 DCGs were selected as prognostic signatures, and patients in the high-risk group had a lower overall survival (OS). The lower infiltration levels of immune cells and the higher expression levels of ...
The 4-DCGs signature prognosis model we constructed could predict the survival rate, immune activity, and chemoradiotherapy responsiveness of LUAD patients....